Exagen Inc. (XGN) Next Earnings Date & Expected ±12.5% Move

Per the Roarable RQD rating, XGN scores 36 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:

• Fundamental Cash Engine (4 / 20): Return on invested capital is -35% and the free cash flow yield is -6.77%. This is the weakest pillar and signals that the business is not currently generating cash relative to the capital deployed. For a prospective investor, the upside case depends on a turnaround in operating cash generation that the source data does not show yet.
• Whale / 13F Flow (14 / 20): This pillar reflects institutional accumulation and options positioning. It is the strongest pillar, indicating some institutional interest, though the holder-level detail is not available in source data.
• Insider Conviction (3 / 20): This pillar reflects SEC Form 4 and Congressional PTR cluster flow. It scores low, and the news wire contains reported insider sales alongside an insider purchase (see Recent Catalysts). Mixed insider activity limits the conviction signal.
• Macro Regime Fit (7 / 20): Beta is 1.0, meaning the stock moves in line with the broader market, with added sensitivity to sector conditions. The score reflects limited defensive characteristics.
• Forensic Balance Sheet (8 / 20): Altman Z-Score is 0.2, Piotroski F-Score is 4 out of 9, and Debt/Equity is 1.28. These figures point to financial distress risk and weak balance-sheet quality. This is a material valuation tradeoff: any equity upside must be weighed against a leveraged, cash-consuming structure.

Taken together, the rating frames XGN as a high-risk, cash-consuming company. The valuation tradeoff for a prospective investor is that the stock's recent price strength and reported institutional interest must be weighed against weak profitability, negative cash flow, and a stressed balance sheet. This is an analytical framing, not personalized financial advice.

Per the SEC financials, revenue grew from $52.5M in FY 2023 to $66.6M in FY 2025, while operating losses, net losses, and negative free cash flow persisted in each reported period. Operating margin is -21.1% and net margin is -30%. Return on invested capital is -35% per the market data section. The Altman Z-Score is 0.2 and the Piotroski F-Score is 4 out of 9, both per the Roarable RQD rating, indicating financial stress and weak fundamental quality. Cash of $32.2M against debt of $22.3M at FY 2025 shows a modest net cash position, though Debt/Equity of 1.28 indicates leverage relative to equity.

Per the recent news and catalysts feed:

• Catalyst (green): A TD Cowen price target raise from USD 10 to USD 11 is listed as a catalyst.
• Risk Watch (red): A Q2 2026 earnings headline notes a narrower-than-expected loss and a share price lift of 4.15%. It is flagged as a risk-watch item, and the source summary for that item is not a usable description of the company.
• Market Wire (yellow): Multiple items report director and CEO share transactions, including a director purchase of $104,440 in XGN stock, a CEO sale of 34,294 shares, and an initial ownership report of 2.6 million shares by a director. A StockInvest.us forecast item is also listed without further detail.

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals.

• What is the company's specific product portfolio, customer base, and revenue concentration?
• What are the forward earnings and EBITDA expectations, given that P/E and EV/EBITDA are not available?
• What are the terms, maturities, and covenants of the $22.3M debt, and can operating cash flow support it?
• What is the actual composition and size of the insider and institutional ownership positions?
• What drove the Q2 2026 narrower-than-expected loss, and does it reflect a durable improvement in cash generation?